| | | |  | | | | By Jason Mast Adobe In a best case scenario, the drug could provide a new treatment for young patients who have exhausted every other door. Read More | | By Ed Silverman Mike Reddy for STAT Voluntary licensing holds some promise for improving drug access in low- and middle-income countries, but hurdles remain. Read More | | By Jason Mast Wikimedia Commons The results could provide a lifeline for Geron and set up a new treatment for the blood disorders, known as myelodysplastic syndromes, or MDS. Read More | | Sponsored Insight by Mirati A new treatment option is now available for the 2L KRASG12C-mutated NSCLC patient population Built for the challenge of KRASG12C, a new treatment option has been approved by the FDA for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic NSCLC as determined by an FDA approved test, and who have received at least one prior systemic therapy. Learn more about this new treatment option and its robust response to a relentless disease. | | By Jonathan Wosen Adobe The San Diego-based biotech announced Thursday that the termination of its deal with Janssen will result in layoffs and curtailed drug development. Read More | | By Nathan Vardi Adobe New political, regulatory, and structural obstacles may have put an end to the golden era of biotech stocks. Read More | |
No comments